DOW JONES27,081.36-879.44 -3.15%
S&P 5003,128.21-97.68 -3.03%
NASDAQ8,965.61-255.67 -2.77%

Catalent Revises FY20 Sales Guidance From $2.78B-$2.88B To $2.87B-$2.95B vs $2.85B Est.

Fiscal Year 2020 Outlook The Company is raising its previously issued financial guidance, primarily to account for the January 1, 2020 closing of the long-pending acquisition of Bristol-Myers Squibb’s biologics,

Benzinga · 02/03/2020 12:34

Fiscal Year 2020 Outlook

The Company is raising its previously issued financial guidance, primarily to account for the January 1, 2020 closing of the long-pending acquisition of Bristol-Myers Squibb’s biologics, sterile, and oral solid dose product manufacturing and packaging facility in Anagni, Italy. For fiscal 2020, the Company now expects:

  • Revenue in the range of $2.87 billion to $2.95 billion, compared to the previous range of $2.78 billion to $2.88 billion;
  • Adjusted EBITDA in the range of $711 million to $735 million compared to the previous range of $700 million to $730 million; and
  • Adjusted Net Income in the range of $307 million to $331 million compared to the previous range of $300 million to $330 million.
  • A fully diluted share count in the range of 160 million to 161 million shares on a weighted-average basis, compared to the previous range of 159 million to 160 million shares on the same basis, counting the Series A preferred shares as-if converted.